Trial
NCT04157088
Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Prostatic Cancer, Castration-Resistant
Intervention
Darolutamide (Nubeqa, BAY1841788)
Why stopped
The results of the lead-in phase did not fulfill the criteria set for moving into the randomized phase
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-08-04